San Diego, CA -- (SBWIRE) -- 08/13/2015 -- An investor in shares of XOMA Corp (NASDAQ:XOMA), filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by XOMA Corp.

Investors who purchased shares of XOMA Corp (NASDAQ:XOMA) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2015. NASDAQ:XOMA investors should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of XOMA Corp (NASDAQ:XOMA) common shares between November 6, 2014 and July 21, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 6, 2014 and July 21, 2015 defendants made allegedly false and/or misleading statements that Xoma Corporation's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint.

On July 22, 2015, XOMA Corp announced results From Phase 3 EYEGUARD(TM)-B Study. Xoma Corp said that a Phase III trial of its treatment (gevokizumab) for Behcet's disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. The company announced that it will continue to work with its French partner, Servier, to conduct a thorough analysis of the data.

Those who purchased shares of XOMA Corp (NASDAQ:XOMA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com